July industry news: Ipsen partners with Exicure on SNA therapies for neurodegenerative disorders

Written by Neuro Central
Drug development Industry and business Injury, trauma and infection Neurodegeneration and degenerative disease News
AIdriven research projecting new drug developments, Pharmaceutical technology, Innovating medicine with advanced predictive analytics

In July's industry news round-up: Ipsen has partnered with Exicure to research, develop and commercialize SNA therapies for neurodegenerative disorders; significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy has been shown for Roche’s risdiplam; Posit Science has identified the first effective intervention to address cognitive deficits that can persist for years after a mTBI; ClearPoint Neuro and Blackrock Neurotech to develop an automated surgical solution for implanting Brain Computer Interfaces into patients; and Wave Life Sciences have initiated dosing in Phase Ib/IIa FOCUS-C9 clinical trial of WVE-004 in amyotrophic lateral sclerosis and frontotemporal dementia.  Take a look at July’s headlines below: Ipsen partners with Exicure on SNA therapies for neurodegenerative disorders  Evrysdi® (risdiplam)...

To view this content, please register now for access

It's completely free